FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP
SIAILMLINI	OI CITANOLS	IN DENEI ICIAE	OWNERSHI

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* STAAB THOMAS R II (Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200					BI	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [BCRX] 3. Date of Earliest Transaction (Month/Day/Year) 07/01/2014											ationship of Reporting k all applicable) Director Officer (give title		10% O	wner	
					07/												below) below) Senior Vice President and CFO				
(Street) DURHA (City)			27703 (Zip)		- 4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. I Lin	e) X Forn Forn	ual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - No	n-Deriv	ative	e Se	curit	ies Ad	cqu	iired, [Disp	osed o	of, or	Bene	eficia	ly Owne	d				
1. Title of Security (Instr. 3)			Date	. Transaction ate Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		е,	Transaction Code (Instr.					(A) or 3, 4 and	Benefi Owned	es For ially (D) Following (I) (n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
									ĺ	Code	v	Amount	()	A) or D)	Price		ea ction(s) 3 and 4)			(Instr. 4)	
Common	Stock			07/02	1/2014					M		3,12	5	A	\$4.7	3 14	147,426		D		
Common Stock ⁽¹⁾			07/0	1/201	/2014				S		3,12	5	D	\$13	14	4,301		D			
		7	able II -	Deriva (e.g., p	tive s	Sec call	uritie s, wa	s Acc arrants	quir s, o	ed, Di	spo s, c	sed of onverti	, or E ble s	Benef ecuri	icially ties)	/ Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		of E		Exp	6. Date Exercisal Expiration Date Month/Day/Year			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price o Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Dat Exe	te ercisable		xpiration ate	Title	O N O	umber						
Emp. Stock Option (Right to Buy) ⁽¹⁾	\$4.73	07/01/2014			М			3,125	03.	8/01/2013	03	3/01/2022	Comm		3,125	\$0	15,50	00	D		

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 26, 2014.

/s/ Alane P. Barnes, by power of attorney

07/02/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.